Adocia to Hold Its Annual Shareholders’ Meeting on May 28th, 2020 at Its Headquarter in Lyon
April 20 2020 - 12:00PM
Business Wire
Regulatory News:
ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC the
“Company”and “Adocia”), a clinical stage biopharmaceutical company
focused on diabetes treatment with innovative formulations of
approved proteins, will hold its annual shareholders’ meeting
(“AGM”) on May 28th, 2020, at 10 am at the Company’s headquarter,
115 avenue Lacassagne, 69003, Lyon, France. The notice of this
shareholders’ meeting serving as convening notice is published
today, in the French Bulletin des Annonces Légales Obligatoires
(“BALO”), and includes the agenda, the proposed resolutions as well
as instructions to participate and vote for this meeting.
This notice is also available on the company’s website:
https://www.adocia.com/investors-welcome/shareholders-meeting/.
All documentation regarding this AGM will be made available to
shareholders in accordance with existing regulations and will be
available on the company’s website from May 4th, 2020.
Precisions regarding the AGM:
Only shareholders having registered their shares at least two
business days prior to the date of the AGM, by midnight Paris time,
will be able to participate in the AGM.
Shareholders holding bearer shares (“actions au porteur”) will
need to obtain a certificate of shareholding (“attestation de
participation”) from their brokers. This certificate must be
attached to the proxy form or to the appropriate voting form if
shareholders wish to designate a proxy or vote by post. The
“attestation de participation” may replace the admission card for
shareholders wishing to attend the AGM in person.
Each shareholder may submit a question in writing to the Board
of Directors, this question being treated during the shareholders
meeting. Questions should be sent by registered mail with return
receipt to the following address: ADOCIA, 115 avenue Lacassagne -
69003 Lyon or electronic communication to the following address:
ag2020@adocia.com.
The written question must imperatively be accompanied by a
certificate of attendance in order to be treated and must be sent
no later than the fourth business day preceding the date of the
general meeting. Shareholders may obtain the legal documentation in
preparation of the AGM as described in the article R.225-83 of the
French Commercial Code by sending a request:
• By regular mail to: Adocia - Service Relations Investisseurs –
115 avenue Lacassagne, 69003 Lyon, or
• By e-mail to: ag2020@adocia.com.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
other metabolic diseases. In the diabetes field, Adocia’s portfolio
of injectable treatments is among the largest and most
differentiated of the industry, featuring five clinical-stage
products. Adocia aims to expand its portfolio towards the treatment
of other metabolic diseases and their comorbidities.
The proprietary BioChaperone® technological platform is designed
to enhance the effectiveness and/or safety of therapeutic proteins
while making them easier for patients to use. Adocia customizes
BioChaperone to each protein for a given application. Adocia’s
clinical pipeline includes four novel insulin formulations for the
treatment of diabetes: two ultra-rapid formulations of insulin
analog lispro (BioChaperone® Lispro U100 and U200), a combination
of basal insulin glargine and rapid-acting insulin lispro
(BioChaperone® Combo) and a combination of a prandial insulin with
amylin analog pramlintide (M1 PRAM - ADO09). It also includes an
aqueous formulation of human glucagon (BioChaperone® Glucagon) for
the treatment of hypoglycemia. Adocia preclinical pipeline includes
a combination of insulin glargine with GLP-1 receptor agonists
(BioChaperone® Glargine GLP-1) for the treatment of diabetes and a
ready-to-use combination of glucagon and a GLP-1 receptor agonist
(BioChaperone® Glucagon GLP1) for the treatment of obesity. Adocia
is also exploring in preclinic the potential of its M1 PRAM
combination to treat people with type 2 diabetes suffering from
neurological comorbidities, including Alzheimer’s disease.
In 2018, Adocia and Chinese insulin leader Tonghua Dongbao
entered a strategic alliance. In April 2018, Adocia granted Tonghua
Dongbao licenses to develop and commercialize BioChaperone Lispro
and BioChaperone Combo in China and other Asian and Middle Eastern
territories. The licensing agreements included USD 50 million
upfront and up to USD 85 million development milestones, plus
double-digit royalties on sales. In June 2018, Tonghua Dongbao
agreed to manufacture and supply active pharmaceutical ingredients
insulin lispro and insulin glargine to Adocia globally, excluding
China, to support Adocia’s portfolio development and
commercialization.
Adocia aims to deliver “Innovative medicine for everyone,
everywhere.”
To learn more about Adocia, please visit us at
www.adocia.com
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Reference Document filed with the
French Autorité des marchés financiers on April 12, 2019 (a copy of
which is available at www.adocia.com) and to the development of
economic conditions, financial markets and the markets in which
Adocia operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Adocia or
not currently considered material by Adocia. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance or achievements of Adocia to be materially
different from such forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200420005619/en/
Adocia Gérard Soula Chairman and CEO
contactinvestisseurs@adocia.com Ph.: +33 4 72 610 610
Adocia Press Relations Europe MC Services AG
Raimund Gabriel adocia@mc-services.eu Ph.: +49 89 210 228 0
Adocia Investor Relations USA The Ruth Group Tram
Bui tbui@theruthgroup.com Ph.: +1 646 536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2024 to May 2024
Adocia (EU:ADOC)
Historical Stock Chart
From May 2023 to May 2024